Theravance Biopharma, Inc.
US ˙ NasdaqGM ˙ KYG8807B1068

SecurityTBPH / Theravance Biopharma, Inc.
InstitutionWalleye Capital LLC
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Walleye Capital LLC ownership in TBPH / Theravance Biopharma, Inc.

On February 13, 2026 - Walleye Capital LLC filed a 13F-HR form disclosing ownership of 0 shares of Theravance Biopharma, Inc. (US:TBPH) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 14, 2025 disclosing 29,395 shares of Theravance Biopharma, Inc.. The current value of the position is $0 USD.

Walleye Capital LLC has a history of taking positions in derivatives of the underlying security (TBPH) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

TBPH / Theravance Biopharma, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 0 -100.00 0
2025-11-14 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 29,395 -5,264 -15.19 429 12.30 0.0016
2025-08-13 2025-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 34,659 34,659 382 0.0015
2022-11-14 2022-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 0 -82,758 -100.00 0 -100.00
2022-08-19 2022-06-30 13F/A-1 THERAVANCE BIOPHARMA COM G8807B106 82,758 44,958 118.94 750 107.76 0.0207
2022-08-08 2022-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 82,758 44,958 750 0.0207
2022-05-27 2022-03-31 13F/A-01 THERAVANCE BIOPHARMA COM G8807B106 37,800 37,800 361 0.0096
2022-05-16 2022-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 37,800 37,800 361 0.0073
2021-11-15 2021-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 0 -16,688 -100.00 0 -100.00
2021-08-16 2021-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 16,688 16,688 242 0.0082
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F THERAVANCE BIOPHARMA COM Call 0 -100.00 0 n/a n/a n/a
2025-11-14 2025-09-30 13F THERAVANCE BIOPHARMA COM Call 8,400 123 n/a n/a n/a
2023-05-15 2023-03-31 13F THERAVANCE BIOPHARMA COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-02-14 2022-12-31 13F THERAVANCE BIOPHARMA COM Call 10,100 -85.57 113 -84.08 n/a n/a n/a
2022-11-14 2022-09-30 13F THERAVANCE BIOPHARMA COM Call 70,000 710 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F THERAVANCE BIOPHARMA COM Put 0 -100.00 0 n/a n/a n/a
2025-11-14 2025-09-30 13F THERAVANCE BIOPHARMA COM Put 1,000 15 n/a n/a n/a
2023-02-14 2022-12-31 13F THERAVANCE BIOPHARMA COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-11-14 2022-09-30 13F THERAVANCE BIOPHARMA COM Put 26,400 268 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.